Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial /
Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined.This pre-specif...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2019
|
| Sorozat: | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
74 No. 9 |
| Tárgyszavak: | |
| doi: | 10.1016/j.jacc.2019.03.013 |
| mtmt: | 32688478 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/27008 |